Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...

Professors Tom Powles and Peter Schmid recently delivered results from their phase three clinical trials during Sunday's ...

NIH clinical trial results expand treatment options for this disease.

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Matthew Galsky, MD, discusses why some physicians were surprised at the positive outcomes of nivolumab trials in bladder ...

The European Society Medical for Medical Oncology Congress 2024 in Barcelona This is the fifth time in recent years that ...

Aethlon's Hemopurifier® is a clinical stage immunotherapeutic device designed to combat cancer. Read the full article at Investorideas.com According to News-Medical.net, "Immunotherapy, which works ...

Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large ...

Two new cancer drugs will be funded in the next two months as part of the Government’s $604 million boost to the budget of New Zealand’s drug-buying agency Pharmac. Pembrolizumab, known as Keytruda, ...

Pharmac’s Director of Pharmaceuticals, Geraldine MacGibbon, says Pharmac is really pleased to announce our first decision for cancer medicines since the Government provided additional funding in June ...